Table 2.

Association between NOS1AP genotype and all-cause mortality (n = 79) in 1113 incident calcium channel blocker users

		Model 1*		Model 2†		Model 3‡
	Cases	HR	(95% CI)	HR	(95% CI)	HR	(95% CI)
Dihydropyridine calcium channel blockers (n = 52)
TT	12	Ref.		Ref.		Ref.
TG	30	2.57	(1.24, 5.34)	2.50	(1.20, 5.19)	2.50	(1.19, 5.22)
GG	10	3.18	(1.18, 8.58)	3.18	(1.18, 8.61)	3.25	(1.19, 8.85)
Amlodipine
TT	4	Ref.		Ref.		Ref.
TG	9	1.47	(0.45, 4.84)	1.48	(0.45, 4.86)	1.25	(0.38, 4.18)
GG	4	2.65	(0.63, 11.1)	2.39	(0.58, 9.89)	2.56	(0.61, 10.8)
Nifedipine
TT	7	Ref.		Ref.		Ref.
TG	16	3.48	(1.19, 10.2)	3.68	(1.22, 11.1)	3.95	(1.28, 12.2)
GG	5	2.65	(0.53, 13.3)	2.54	(0.50, 12.8)	2.27	(0.42, 12.1)
Nondihydropyridine calcium channel blockers (n = 27)
TT	13	Ref.		Ref.		Ref.
TG	9	0.83	(0.35, 2.01)	0.81	(0.34, 1.98)	0.80	(0.33, 1.96)
GG	5	0.94	(0.30, 2.97)	0.95	(0.30, 3.01)	1.02	(0.29, 3.54)
Verapamil
TT	5	Ref.		Ref.		Ref.
TG	4	0.65	(0.15, 2.86)	0.56	(0.12, 2.57)	0.46	(0.09, 2.35)
GG	3	0.33	(0.03, 3.15)	0.50	(0.04, 6.22)	0.38	(0.02, 5.67)
Diltiazem
TT	8	Ref.		Ref.		Ref.
TG	5	0.76	(0.24, 2.41)	0.76	(0.24, 2.41)	0.73	(0.22, 2.37)
GG	2	0.73	(0.15, 3.53)	0.75	(0.15, 3.63)	0.73	(0.12, 4.22)

^*Model 1: adjusted for age and gender.

^†Model 2: adjusted for age, gender and QTc interval.

^‡Model 3: adjusted for age, gender, QTc interval, hypertension and diabetes mellitus.